This hypothesis was initially examined in breast cancer patients, where increased expression of ANKHD1 statistically correlates with a reduction in relapse-free survival (the length of time after the initial cancer treatment that the patient lives without any symptoms of that cancer [21]) [10,38], a change which varies depending on breast cancer subtype. The gene discussed is ANKHD1; the disease is breast carcinoma.